Yersinia pestis infection future or investigational therapies: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Future and Investigational Therapies== | ==Future and Investigational Therapies== | ||
Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include: | Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:<ref name=Mandell>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref> | ||
* Protection from airborne infection | * Protection from airborne infection | ||
* Inhaled administration | * Inhaled administration | ||
A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against this type of infection as well. Other options include: | A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against this type of infection as well. Other options include:<ref name=Mandell>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref> | ||
* Aerosolized monoclonal antibodies | * Aerosolized monoclonal antibodies | ||
* Attenuated form of [[Yersinia pseudotuberculosis]] | * Attenuated form of [[Yersinia pseudotuberculosis]] | ||
Revision as of 19:30, 25 July 2014
|
Yersinia pestis infection Microchapters |
|
Differentiating Yersinia Pestis Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Yersinia pestis infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Yersinia pestis infection future or investigational therapies |
|
FDA on Yersinia pestis infection future or investigational therapies |
|
CDC on Yersinia pestis infection future or investigational therapies |
|
Yersinia pestis infection future or investigational therapies in the news |
|
Blogs on Yersinia pestis infection future or investigational therapies |
|
Risk calculators and risk factors for Yersinia pestis infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Future and Investigational Therapies
Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:[1]
- Protection from airborne infection
- Inhaled administration
A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against this type of infection as well. Other options include:[1]
- Aerosolized monoclonal antibodies
- Attenuated form of Yersinia pseudotuberculosis
References
- ↑ 1.0 1.1 Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.